# Stem cells weekly update — no public article change Date: 2026-07-20 Site: Managing Expectations / Health Primary article: `/blog/articles/stem-cells-evidence-costs-risks-global-guide.html` Launch source note: `/research/health/stem-cells-evidence-costs-risks-source-note-2026-06-20.md` Previous weekly note: `/research/health/stem-cells-weekly-update-2026-07-06.md` Raw local check file: `/tmp/stem_weekly_check_2026-07-20.json` during this cron run ## Bottom line No substantive source-grounded change was found that warrants changing the public stem-cell report this week. FDA's approved cellular/gene therapy list still shows the same July 1, 2026 update captured in the July 6 maintenance note; no newer FDA/Health Canada/ISSCR/AAOS/NCI position change, broad stem-cell approval, professional-society guidance shift, high-quality practice-changing trial result, or major safety warning was identified in this run. The public article should remain unchanged: established hematopoietic transplant/cell-therapy medicine is real and condition-specific; many commercial regenerative, orthopedic, exosome, anti-aging, neurologic and medical-tourism claims remain investigational, anecdotal, unsupported, or high-risk depending on the exact product and indication. ## Sources checked this run ### United States — FDA / NIH / NCI / ClinicalTrials.gov - FDA, **Important Patient and Consumer Information About Regenerative Medicine Therapies** URL: https://www.fda.gov/vaccines-blood-biologics/consumers-biologics/important-patient-and-consumer-information-about-regenerative-medicine-therapies Retrieval: HTTP 200 by direct scripted fetch. Metadata observed: published/modified 2024-04-08. Finding: FDA's core consumer warning remains unchanged for article purposes. FDA continues to frame unapproved regenerative products, including stem cells, stromal vascular fraction, umbilical cord/cord blood stem cells, Wharton's jelly products, ortho-biologics and exosomes, as requiring proper FDA oversight/approval and as linked to serious reported harms such as blindness, tumor formation and infections. - FDA, **Approved Cellular and Gene Therapy Products** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/approved-cellular-and-gene-therapy-products Retrieval: HTTP 200 by direct scripted fetch. Metadata observed: published/modified 2026-07-01. Finding: No newer change was identified beyond the July 1 FDA list update already reflected in the July 6 public article callout. The proper framing remains narrow and label-specific approvals, not a blanket approval for cash-pay stem-cell, exosome, orthopedic, anti-aging, neurologic or medical-tourism clinic claims. - FDA, **Regenerative Medicine Advanced Therapy Designation** URL: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/regenerative-medicine-advanced-therapy-designation Retrieval: HTTP 200. Metadata observed: 2025-11-04. Finding: RMAT remains a development/designation pathway, not consumer proof that broad clinic-marketed stem-cell products are approved. - NIH, **Stem Cell Basics** URL attempted: https://stemcells.nih.gov/info/basics/stc-basics/ Retrieval: HTTP 403 in this cron environment. Finding: No new article change was made from a blocked source. The launch source note already preserves the NIH baseline distinction among pluripotent, adult/somatic and blood-forming stem cells. - NCI, **Stem Cell and Bone Marrow Transplants for Cancer** URL: https://www.cancer.gov/about-cancer/treatment/types/stem-cell-transplant Retrieval: HTTP 200. Finding: NCI's established transplant-medicine framing remains consistent with the article: stem-cell/bone-marrow transplant is specialist treatment for selected cancers/blood/immune contexts, with serious risks and long recovery. - ClinicalTrials.gov v2 API, broad scan sorted by last update for stem-cell therapy, mesenchymal stromal cells, induced pluripotent stem cells, exosome therapy, HSCT, Parkinson's, diabetes, spinal-cord injury and arthritis. Retrieval: HTTP 200 after correcting the API sort syntax to `LastUpdatePostDate:desc`. Examples observed: NCT06998706 autologous basal-layer stem-cell transplantation for interstitial lung disease; NCT07715045 umbilical-cord mesenchymal stromal-cell secretome for moderate rheumatoid arthritis, listed as a randomized double-blind placebo-controlled trial and updated 2026-07-20; NCT07243561 umbilical-cord MSC-derived exosomes for childhood autism; additional registry activity for iPSC/disease-characterization and transplant-related studies. Finding: These are registry activity signals. The rheumatoid-arthritis secretome listing is notable enough to track, but this run did not identify published results or regulator/practice-changing evidence requiring article edits. The correct label remains `promising/under study`, not proven commercial therapy. ### Canada — Health Canada - Health Canada, **Unauthorized cell therapy warning** URL: https://recalls-rappels.canada.ca/en/alert-recall/health-canada-advising-canadians-about-potential-health-risks-associated-unauthorized Retrieval: HTTP 200. Finding: No new Health Canada warning was found that changes the article. The 2019 warning remains relevant: unauthorized cell therapies may be unproven and may carry serious infection, life-altering or life-threatening risks. - Health Canada, **Policy Position Paper — Autologous Cell Therapy Products** URL: https://www.canada.ca/en/health-canada/services/drugs-health-products/biologics-radiopharmaceuticals-genetic-therapies/applications-submissions/guidance-documents/cell-therapy-policy.html Retrieval: timed out on repeated direct fetch attempts in this cron environment. Finding: No article change was made from a timed-out source. Prior notes already preserve Health Canada's baseline policy framing. ### Guidelines / professional societies - ISSCR, **Guidelines for Stem Cell Research and Clinical Translation** URL: https://www.isscr.org/guidelines Retrieval: HTTP 200. Finding: No new guideline change surfaced. ISSCR still supports the article's core frame: rigorous oversight, transparency, evidence-based translation and caution around patient-funded unproven interventions. - AAOS OrthoInfo, **Use of Stem Cells in Orthopaedics** URL: https://orthoinfo.aaos.org/en/treatment/use-of-stem-cells-in-orthopaedics/ Retrieval: HTTP 200, redirected to `orthoinfo.org`. Finding: AAOS caution remains consistent with the article: orthopedic stem-cell uses are still being tested; claims of cartilage/tendon/spine regeneration should not be treated as established proof without controlled evidence and regulator oversight. ### Global regulatory scan - EMA, **Advanced therapy medicinal products: Overview** URL: https://www.ema.europa.eu/en/human-regulatory-overview/advanced-therapy-medicinal-products-overview Retrieval: HTTP 200. Finding: EMA overview continues to support the article's Europe wording: ATMPs are regulated medicines requiring appropriate authorization; no new article-changing EU event was identified in this run. - UK MHRA, **Advanced therapy medicinal products: regulation and licensing in UK** URL: https://www.gov.uk/guidance/advanced-therapy-medicinal-products-regulation-and-licensing Retrieval: HTTP 200. Metadata/page date observed: last updated 2025-03-06. Finding: Confirms UK ATMP/regenerative products remain regulated medicines; no new article wording required. - Japan PMDA/MHLW, **Strategy of SAKIGAKE by MHLW** URL: https://www.pmda.go.jp/english/review-services/reviews/advanced-efforts/0001.html Retrieval: HTTP 200. Finding: Japan remains a distinctive accelerated-pathway jurisdiction for innovative medical products, including regenerative medical products, but no new policy event was found that changes the article. - Australia TGA, **Autologous human cells and tissue products** guidance URL attempted: https://www.tga.gov.au/resources/resource/guidance/autologous-human-cells-and-tissue-products Retrieval: timed out in this cron environment. Finding: No article change was made from a timed-out source. - Singapore HSA, **Cell, Tissue and Gene Therapy Products** URL: https://www.hsa.gov.sg/ctgtp/ Retrieval: HTTP 200 after several older CTGTP paths returned 404. Finding: Singapore's HSA CTGTP page confirms a regulated product category to verify directly before patient-facing claims; no new article-changing policy event was identified. ### Peer-reviewed / PubMed scan - PubMed ESearch/ESummary, Entrez-date scan from 2026-07-06 to 2026-07-20 for controlled/clinical cell therapy, mesenchymal stromal/stem cells, iPSCs, exosomes, safety and adverse-event language. Retrieval: HTTP 200. Broad query returned many newly indexed items. Examples surfaced: autologous stem-cell transplantation conditioning/outcomes in acute myeloid leukemia; lupus nephritis review material; amniotic epithelial-cell exosome preclinical work; exosome/nanocomposite stroke-model work; hair-transplantation regenerative adjunct review. Finding: No single high-quality randomized or large controlled clinical result was identified that changes the public evidence labels this week. - PubMed HSCT outcomes/safety scan from 2026-07-06 to 2026-07-20. Retrieval: HTTP 200. Finding: Newly indexed specialist HSCT literature was found, but it does not change the public article's broad distinction between established hospital transplant medicine and commercial regenerative-clinic marketing. - PubMed frontier-indications scan from 2026-07-06 to 2026-07-20 for Parkinson's, diabetes, spinal cord, arthritis, autoimmune disease and stem-cell/iPSC/exosome terms. Retrieval: HTTP 200. Finding: The scan surfaced translational/preclinical/review items and registry-adjacent topics. No practice-changing evidence was identified for commercial anti-aging, neurologic, orthopedic, exosome or medical-tourism claims. ## What changed - A new dated maintenance/source note was created to record this week's official, regulatory, trial-registry and literature checks. - No public-facing article, Health page, evidence-label, pricing, policy table or medical-tourism wording change is recommended this week. ## What did not change - FDA's consumer warning remains the primary safety anchor for unapproved regenerative products. - FDA's approved cellular/gene therapy list still supports the article's point that approvals are narrow and indication-specific. - Health Canada's unauthorized-cell-therapy warning remains relevant. - NCI's transplant-medicine explanation remains unchanged. - ISSCR/AAOS cautionary framing remains unchanged. - ClinicalTrials.gov activity remains research/trial activity, not general proof for commercial wellness, orthopedic, exosome, anti-aging, neurologic or medical-tourism clinic claims. ## Suggested article edits None this week. Do not add dosing, clinic endorsement, patient travel advice, trial recruitment advice, cure framing, or implied approval for unapproved commercial products. ## Medical/editorial boundary This note is source tracking only. It is not medical advice, diagnosis, treatment guidance, dosing guidance, trial recruitment advice, clinic endorsement, or encouragement to travel for treatment.